Phase 1RecruitingINTERVENTIONAL
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
ClinicalTrials.gov · NCT07527195 · Registry updated: 2026-05-07
- Condition / research focus
- Obesity
- Sponsor
- Novo Nordisk A/S
- Countries with listed sites
- Denmark
- Registry dates and results
- Start: 2026-04-10. Completion: 2028-06-09 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Cagrilintide (drug)
- Semaglutide (drug)
- Placebo cagrilintide (drug)
- Placebo semaglutide (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Aarhus Universitetshospital, Steno Diabetes Center Aarhus
Aarhus N, Denmark
Site recruitment: Recruiting